MarketLens

What Do the SYNAPSE-CMT Phase 2a Results Mean for NMD Pharma

4 months ago

SHARE THIS ON:

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

Already a Pro member? Log in

SHARE THIS ON:

What Do the JADE101 Phase 1 Interim Results Reveal

4 months ago

What Happened with aTyr Pharma's Initial Phase 3 Trial

5 months ago

What Do the Povorcitinib Trial Results Mean for Incyte

7 months ago

What Do UNFI's Mixed Q2 Results Really Mean for Investors

7 months ago

Scholar Rock Holding Corporation (SRRK) Discusses FDA Approval and Clinical Impact of ISEMBYLD in SMA Treatment Transcript

Scholar Rock Holding Corporation discussed FDA approval of ISEMBYLD for SMA treatment. The transcript covers clinical impact, but no specific efficacy figures, timelines, or financial metrics were pro...

SRRK

Stock News•3 months ago

NMD Pharma Announces Publication Identifying Neuromuscular Junction Transmission Failure as a Novel Contributor to Age-Related Muscle Weakness

NMD Pharma published research in The Journal of Clinical Investigation identifying NMJ transmission failure as a reversible contributor to sarcopenia. Preclinical studies showed ClC-1 inhibition impro...

Stock News•3 months ago

Annexon: Perfect Complement To A Speculative Biotech Portfolio

Annexon's tanruprubart showed a 2.4-fold GBS-DS improvement in Phase 3, positioning it for standard-of-care status. MAA submitted to EMA; FDA BLA planned for 2026.

ANNX